AIIMS Delhi to start Covaxin trials on children in few days, say sources
"AIIMS Patna has started trials in the age of 12-18 years, we have started clinical trials of Covaxin after registration for this age only," said Dr Prabhat Kumar Singh, Director, AIIMS, Patna.
New Delhi: After All India Institute of Medical Sciences (AIIMS), Patna, now AIIMS Delhi is also planning to start the Paediatric clinical trials of the indigenous Bharat Biotech’s COVID-19 vaccine “Covaxin” in few days, sources said on Thursday.
The paediatric trials for Covaxin started in AIIMS Patna on Tuesday after Bharat Biotech’s COVID-19 vaccine received the Drugs Controller General of India (DCGI) nod to conduct clinical trials on children on May 11.
“AIIMS Patna has started trials in the age of 12-18 years, we have started clinical trials of Covaxin after registration for this age only,” said Dr Prabhat Kumar Singh, Director, AIIMS, Patna.
“After these trials, the age group will be 6-12 years and then 2-6 years but now we have started trails in the age group of 12-18 years,” he added.
VK Paul, Member (Health), Niti Aayog had earlier said, “Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.”
India started the world’s largest vaccination drive on January 16 this year in a phased manner with healthcare workers (HCWs) getting inoculated first. The vaccination of frontline workers (FLWs) started on February 2.
The next phase of Covid-19 vaccination commenced from March 1 for those over 60 years of age and for people aged 45 and above with specified co-morbid conditions. India launched vaccination for all people aged more than 45 from April 1.
The third phase of the vaccination started on May 1 for the beneficiary aged between 18-44.
India has three COVID-19 vaccines – Bharat Biotech’s Covaxin, Serum Institute’s Covishield, and Russia’s Sputnik V. Covaxin and Covishield are being manufactured in India.